Alterity Therapeutics Limited

What they do

Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) was incorporated in Australia on November 11, 1997, and is headquartered in Melbourne. The company's mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders. Its ordinary shares are primarily quoted on the ASX, and its American Depositary Shares, each representing 12 ordinary shares, trade on the Nasdaq Capital Market under the symbol ATHE.

Revenue drivers

• Neurology / neurodegenerative disease programs — Alterity describes itself as developing therapeutic drugs for neurodegenerative diseases, with a current focus on Parkinsonian and other movement disorders. No approved products, product revenue, segment revenue or partnership revenue are identified in the filing excerpt.

Recent performance

The excerpt provided does not include the company's income statement, balance sheet or cash flow figures for the fiscal year ended June 30, 2026. It states that 217,508,862 ordinary shares were outstanding as of June 30, 2026, and that financial statements are prepared in Australian dollars under IFRS as issued by the IASB. The filing also notes that ADSs have traded under the symbol ATHE on Nasdaq since the April 8, 2019 name change to Alterity Therapeutics Limited.

Strategy

The stated mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders. The company prepares financial statements in Australian dollars under IFRS and maintains a primary ASX listing alongside its Nasdaq ADS listing. It also complies with Australian Corporations Act 2001 and ASX Listing Rules disclosure requirements. No product approval, partnership, licensing or commercialization strategy is described in the excerpt.

Risks

• Clinical-stage development risk — Alterity describes itself as developing therapeutic drugs and identifies no approved products in the excerpt, so its prospects depend on the success of those development programs.
• Forward-looking statement uncertainty — The company states that forward-looking statements are predictions inherently subject to known and unknown risks that could cause actual results to differ materially.
• Dual-market disclosure and compliance burden — As an ASX-listed company with Nasdaq-traded ADSs, Alterity must comply with both Australian Corporations Act 2001 and ASX Listing Rules disclosure requirements in addition to U.S. reporting obligations.
• Reliance on external capital — With no product revenue identified in the excerpt, ongoing operations depend on financing, and the filing references Registration Statements on Form S-8 (File Nos. 333-228671, 333-248980, 333-251073) and Form F-3 (File No. 333-274816).

Outlook

The filing excerpt contains no management guidance or forecast for future periods. It provides only historical and structural information, including the June 30, 2026 fiscal year end and the June 30, 2026 ordinary share count. Readers should refer to Item 3.D. “Risk Factors” and the financial statements for forward-looking detail.